



Partner Profile - Generis and INCONSULT

With more than 20 years of experience, INCONSULT provide consulting, BPO and systems implementation services across the complete pharmaceutical regulatory process chain. Their dedicated team have been working with CARA since 2014 and they have a thorough understanding of its functionality and of the implementation process.

INCONSULT cooperatively develop automation tools and services for regulatory processes such as labelling & artwork management, CCDS implementation tracking, document classification, proof reading and document creation. They have extensive project experience in the area of component based and structured content authoring, as well as offering data cleansing technologies and services to harmonise data across systems and divisions. They also utilise AI & NLP tools to drive and support digitalization initiatives in regulatory space.

Why INCONSULT?

- Integrated view of business and IT
- Understand the big picture
- Ability to relate to industry challenges
- Responsive to customer needs
- Collaborative and flexible
- Experience with systems conversion and migration
- More than 20 years of experience
- Recognised in industry for thought leadership

Why Generis?

- 20 Years experience
- Global reach
- We work to understand your needs and processes, rather than making you move your processes fit to our solution
- Fully integrated CARA Life Science Platform
- Expert teams
- Understanding of global industry challenges.

Previous Experience

INCONSULT and Generis worked together to implement a global Quality / SOP system for one of the top 3 German Life Science companies. The system had to merge two legacy systems (FirstDoc and SCORE) into a single new CARA system, with granular security, change request handling, controlled printing and other typical SOP functionality. The system is in multiple phases of rollout now to over 55,000 users globally. INCONSULT provided services around project management, validation, documentation, testing and configuration support, while Generis provided the requirements-to-configuration activities based on CARA.

Future Plans

There are a number of projects in the pipeline for INCONSULT; currently they aim to facilitate the move from a document centric to a hybrid Document and Data Submission Lifecycle. Generis' vision with the new CARA workspace is to align with this move towards a document and data focused way of working. Inconsult plans to implement new standards for the transmission of structured regulatory information as well as scalable technical solutions to handle the transition from existing standards over the course of the next two to five years. Furthermore, they hope to gain more efficiency by adopting and ensuring interoperability of standards.

About



INCONSULT is an IT-consulting company with focus on information management technologies, serving customers in the conception, creation and support of database and IT solutions. Mostly using standard software solutions, INCONSULT customizes these to meet client specific needs. Working in three distinct business segments the company consults on the design, development and administration of new database solutions; supports customer IT infrastructures and works with clients using common ECM platforms to identify and implement specific solutions in their administrative, commercial and technical departments.

To find out more visit: www.inconsult-online.de



Generis is a UK-headquartered developer of world-class Content and Regulatory Information Management technology for regulated industries globally. Eight of the top 10 global life sciences companies rely on Generis' flagship Intelligent Content Services platform, CARA™ for critical document and information management, including AbbVie, AstraZeneca, Biogen, Gilead, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than half a million users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com

To find out more visit: www.generiscorp.com